Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Disease (PMD)

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

Critère d'inclusion

Primary Mitochondrial Disease

Kusajili – Centralise les essais cliniques mondiaux

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Disease (PMD)

Femme et Homme

Extrait

Critère d'inclusion

Liens